This will help you maximize the TB-500 benefits, such as enhanced muscle growth and repair, while also supporting your weight loss goals
The announcements emphasize obesity indications and upcoming oral GLP1s at $145/month through Medicare/Medicaid/TrumpRx
There is currently no clinical trial evidence, regulatory guidance, or peer-reviewed data supporting the combined use of tesamorelin and retatrutide, and both remain unlicensed in the UK
Give Steven a follow on Substack
Critically, the glucagon component appeared to drive increased energy expenditure and enhanced hepatic lipid oxidation without negating the glucose-lowering benefits conferred by GLP-1 and GIP activity
Well, speaking of that heterogeneity, you've done a lot of work on obesity phenotypes, written a couple of books about it now a popular book, Six Factors to Fit , and now a book for clinicians to use this sort of obesity phenotype framework as part of treatment